Anthropic's Claude identifies novel enzyme system, gene editing stocks decline

Anthropic announced that its AI model, Claude, identified a previously undescribed enzyme system within massive DNA sequence datasets, featuring repetitive sequence patterns similar to CRISPR. This discovery is the first output from the company's new biology lab. Following the announcement, shares of gene editing companies fell on Wednesday, with CRISPR Therapeutics dropping 5.54%, Beam Therapeutics 6.02%, and Prime Medicine 11.58%. The research involved Claude agents searching large DNA databases for reverse transcriptase systems. While the system was identified, Anthropic noted that its primary function remains unknown and it has not been proven to function as a programmable gene editing tool.